Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio

@article{Dwarshuis2019FunctionalizedMI,
  title={Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio},
  author={Nathan Dwarshuis and H. Song and Anokhi Patel and Theresa Kotanchek and K. Roy},
  journal={bioRxiv},
  year={2019}
}
  • Nathan Dwarshuis, H. Song, +2 authors K. Roy
  • Published 2019
  • Chemistry, Biology
  • bioRxiv
    • Adoptive cell therapies (ACT) using chimeric antigen receptor (CAR) T cells have shown promise in treating cancer, but manufacturing large numbers of high quality cells remains challenging. Critically, current T cell expansion technologies only partially recapitulate the in vivo microenvironment found in the human lymph nodes. In these organs, T cells expand at high cell density with autocrine/paracrine signaling, as well as signals from the extracellular matrix (ECM). Here we describe a T cell… CONTINUE READING
    View via Publisher
    biorxiv.org
    1 Citations
    One Citation
    Citation Type

    Citation Type

    How Competitive Is Genetic Programming in Business Data Science Applications?

    References

    SHOWING 1-10 OF 68 REFERENCES
    Improving T Cell Expansion with a Soft Touch.
    • 29
    Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T-cells
    • 95
    T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
    • 18
    Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.
    • 34
    Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
    • 283
    • PDF
    GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
    • 19
    • PDF
    Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    • 750
    Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion
    • 9
    Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
    • 246
    Simplified process for the production of anti-CD19-CAR-engineered T cells.
    • 69